Weight loss, diabetes drugs propel Eli Lilly to better-than-expected forecast for 2024
The popular diabetes treatment Mounjaro pushed Eli Lilly past fourth-quarter forecasts, and the drugmaker expects 2024 to turn out largely better than expected too, as new products build momentum
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The popular diabetes treatment Mounjaro pushed Eli Lilly past fourth-quarter forecasts, and the drugmaker expects 2024 to turn out largely better than expected too, as new products build momentum.
Lilly debuted on Tuesday a forecast for the new year that calls for adjusted earnings ranging from $12.20 to $12.70 per share as its new weight-loss drug Zepbound becomes established following its launch late last year.
Analysts expect earnings of $12.39 per share, according to the data firm FactSet.
Zepound, a new version of Mounjaro, registered about $176 million in sales during the final weeks of the fourth quarter after it became the latest drug approved for a hot area of medicine, chronic weight management.
FactSet says analysts expect around $1.9 billion in sales from Zepbound this year. They see sales climbing to $12 billion in a few years.
Lilly also saw Mounjaro sales climb 65% to $2.21 billion in the fourth quarter compared to the year’s previous quarter.
For 2024, the drugmaker also is awaiting a Food and Drug Administration decision on its potential Alzheimer’s treatment, donanemab. Research has shown that the drug can modestly slow mental decline in patients with the fatal, mind-robbing disease. That hasn't been possible until treatments like Leqembi from the Japanese drugmaker Eisai entered the market the past few years.
In the final quarter of 2023, Lilly booked a $2.19 billion profit. Earnings adjusted for one-time items came to $2.49 per share.
Revenue grew 28% to $9.35 billion.
Analysts expect adjusted earnings of $2.30 per share on $8.95 billion in revenue, according to FactSet.
Lilly shares jumped 5% to $741.50 in premarket trading Tuesday.
The stock price topped $700 for the first time on Monday, and has already set several new all-time high marks just this year. The price of Lilly shares has climbed over 400% since the start of the decade.